Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9173395 | 0.90 | GAA (0.63) | GAAALDH1A1TP53KDM4EGLA | |
| SCHEMBL5184740 | 0.85 | LMNA (0.69) | GAAALDH1A1TP53KDM4EGLA | |
| SCHEMBL17014702 | 0.85 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MAPTNFKB1LMNA | |
| SCHEMBL1298410 | 0.85 | HRH3 (0.51) | GAAALDH1A1TP53KDM4EGLA | |
| SCHEMBL19332211 | 0.85 | ALDH1A1 (0.66) | GAAALDH1A1LMNAKMT2ATSHR | |
| SCHEMBL8338055 | 0.84 | GAA (0.57) | GAAKDM4ENLRP3LMNAKMT2A | |
| SCHEMBL23467914 | 0.84 | GAA (0.69) | GAAALDH1A1TP53KDM4EGLA | |
| SCHEMBL6883565 | 0.83 | GAA (0.57) | GAAALDH1A1TP53KDM4EGLA | |
| SCHEMBL21861384 | 0.83 | POLB (0.65) | GAAALDH1A1KDM4ECYP3A4MAPT | |
| SCHEMBL19627377 | 0.83 | HRH3 (0.50) | GAAALDH1A1MAPTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC | 2019-03-05 | — | — | US | disclosed |
| WO-2017156181-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | GAA 2581/4885ALDH1A1 3448/4885TP53 41/4885 |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | GAA 2713/4885ALDH1A1 2765/4885TP53 124/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | GAA 2713/4885ALDH1A1 2765/4885TP53 124/4885 |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | GAA 2581/4885ALDH1A1 3448/4885TP53 41/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | GAA 2581/4885ALDH1A1 3448/4885TP53 41/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | GAA 2581/4885ALDH1A1 3448/4885TP53 41/4885 |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | GAA 2581/4885ALDH1A1 3448/4885TP53 41/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | GAA 2713/4885ALDH1A1 2765/4885TP53 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.